Apimeds Pharmaceuticals US, Inc.

APUS NYSE SEC CIK 1894525
Follow Apimeds Pharmaceuticals US Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $2.9M
Net income $33.6M +1988.9% vs same quarter last year
EPS, diluted $7.68 +640.8% vs same quarter last year
Operating cash flow −$218.6K +87.3% vs same quarter last year
Revenue by quarter
$282.7K
$2.9M
Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income4 fiscal years
−$8M−$6M−$4M−$2M$0FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$6M
FY24−$1.4M
FY23−$777.7K
FY22-